Latest News and Press Releases

LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences...

LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

LAUSANNE, Switzerland, May 17, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine ...

Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this...

LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...

Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO ...

a-syn PET tracer, ACI-12589, clinically validated in MSA, potentially enables accelerated development of targeted therapeutics and additional a-syn diagnostics Another first for validated...

Seven clinical data readouts expected in 2022Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in...